Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings in Brief: Imagyn Medical

This article was originally published in The Gray Sheet

Executive Summary

Imagyn Medical: Going public via initial offering of 2.5 mil. shares at $11 to $13 each, according to a registration statement filed with SEC. The Laguna Niguel, California-based gynecological and reproductive disorder device firm anticipates net proceeds of approximately $27.1 mil., or $31.3 mil. if underwriters Dillon, Read & Co. and Montgomery Securities fully exercise a 375,000 share over-allotment option. About $7 mil. of the proceeds are earmarked for product introductions, building a sales and marketing network, physician training programs and market development; $5 mil. will go toward R&D; $1.5 mil. will go for purchasing capital equipment; and the remainder will be used for "working capital and general corporate purposes."

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel